NO.853 D001

•	•	Docket No. G SN 09/991,20	—
	FAX COVER SHEET	 Urgent Confidential Action Required Reply Required For Your Info. 	
TO:	Art Unit 1638		RECEIVED
LOCATION:	USPTO		CENTRAL FAX CENTER
Fax No.:	(703) 872-9306 (Before Final Fac	Facsimile No.)	
FROM:	Carol See for Victoria L. Boyd Patent Counsel		
LOCATION:	GENENCOR INTERNATIONAL, II Legal Department 925 Page Mill Road Palo Alto, CA 94304-1013 Tel: 650-846-7549 Fax: 650-845-6504	NC.	
DATE:	November 3, 2003		
NUMBER OF	PAGES TO FOLLOW: 4 SENT E	BY: cas	
Re: Serial No. 09)/991,209, Attorney Docket No. GC648-2		
	ansmittal Letter (1 page) in duplicate, and l irement (2 pages).	Response to	
The original of th	is facsimile will be sent to you via:		
☐ Regular Mail ☐ Overnight Mail ☐ Hand Delivery ☒ Will Not Be Sent			
⊠ Please initial a	acknowledgment of receipt by return facsi	mile	
NOTE: The information contained in this facsimile message is confidential and may be subject to attorney- client privilege and is intended only for the use of the above named individual(s). If you are not the intended			

recipient, you are hereby notified that any dissemination, distribution of this communication is strictly prohibited. If you have received this communication in error, pl ase notify us immediately by telephone (650/846-7517) and return the riginal transmission to us by mail.

ı

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to, Art Unit 1638, Before Final Facsimile No. (703) 872-9306, the Commissioner for Patents, Alexandria, VA 22313-1450 on the date shown below.

Date: November 3, 2003

PATENT Docket No. GC 648-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:

09/991,209

Confirmation No. 6062

Applicant:

Dunn-Coleman et al. November 16, 2001

Filed:

Art Unit:

1638

Examiner:

Kallis, Russell GC648-2

Docket No.: Customer No.: 5100

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated October 3, 2003, enclosed please find the following document: Response to Restriction Requirement (2 pages)

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC648-2). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: November 3, 2003

Registration No. 43,510

Genencor International, Inc. 925 Page Mill Road

Palo Alto, CA 94304-1013

Tel: 650-846-7615 Fax: 650-845-6504

GC648-2 T-RR

11/03/2003

13:53

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to, Art Unit 1638, Before Final Facsimile No. (703) 872-9306, the Commissioner for Patents, Alexandria, VA 22313-1450 on the date shown below,

Date: November 3, 2003

PATENT Docket No. GC 648-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

Appl. No.:

09/991.209

Confirmation No. 6062

NOV 0 3 2003

Applicant:

Dunn-Coleman et al. November 16, 2001

Filed: Art Unit:

1638

Examiner:

Kallis, Russell

Docket No.:

GC648-2 Customer No.: 5100

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Sir:

This communication is in response to the Restriction Requirement mailed October 3, 2003 in the above-identified patent application where the Examiner has required restriction among the following groups:

Group I, Claims 1-33 and 74, drawn to plants transformed with either one expression cassette comprising FAE 1 ferulic acld exterase polynuclotide or two expression cassettes, one comprising a FAE 1 ferulic acid esterase polynucleotide and another expression cassette comprising a xylanase polynucleotide; and

Group II, Claims 34-73, drawn to methods of controlling levels of phenolic acids in the cell walls of transformed plants;

In addition, for each of inventions I and II above, the Examiner has required election of one of the following:

- (A) a barley aleurone targeting seguince. Claims 16, 24 and 55;
- (B) a vacuolar targeting sequence, Claims 18, 19 and 57:
- (C) a golgi targeting sequence, Claims 20, 21, 60 and 61;

GC648-2 RR

Appl. No. 09/991,209 Amdt, dated November 3, 2003 Reply to Office action of October 3, 2003

Page 2

- (D) an apoplast targeting sequence, Claims 17, 22 and 59; and
- (E) an ER targeting sequence, Claims 17, 26, 58, 66 and 69

Applicants hereby elect, with traverse, the invention in Group I, Claims 1-33 and 74. In addition, Applicants hereby elect invention (B).

Applicants traverse this restriction requirement and believe that a search and examination of the entire application can be made without serious burden to the Examiner, see MPEP sections 803 and 808. The search would be within the same class for each claim group.

Applicants reserve the right to file subsequent applications claiming the nonelected subject matter and do not waive any of their rights or abandon any non-elected subject matter. Applicants have fully and completely responded to the Office Action and have made the required election. This application is now in order for early action.

Respectfully submitted,

Date: November 3, 2003

Registration No. 43,510

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650-846-7615 Fax: 650-845-6504